Telix Pharmaceuticals (ASX:TLX) has taken another step in expanding its neuro-oncology portfolio, announcing the submission of a European marketing authorisation application for its brain cancer imaging candidate TLX101-Px.
Telix files for European approval of brain cancer imaging candidate TLX101-Px
February 18, 2026 Australian Biotech
Latest Video
New Stories
-
A new prostate cancer technology moves closer to global trials after strong early results
March 12, 2026 - - Australian Biotech -
Cell therapy company Mesoblast names executive to guide clinical development and medical affairs
March 12, 2026 - - Australian Biotech -
Patrys moves toward first human trial for injectable delirium therapy
March 12, 2026 - - Australian Biotech -
Imugene launches $20 million capital raise to fund expansion of Azer Cel trials
March 12, 2026 - - Australian Biotech -
Australia at a crossroads as the nuclear medicine revolution gathers pace
March 12, 2026 - - Latest News -
New Zealand confirms earlier access to breakthrough cystic fibrosis medicines
March 12, 2026 - - Latest News -
Fundraising racing towards total target as teams and participants prepare to climb
March 11, 2026 - - Latest News

